Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$26.11 1.8  7.3%

Last Trade - 21/04/21

Mid Cap
Market Cap £630.9m
Enterprise Value £404.8m
Revenue £n/a
Position in Universe 2928th / 6852

Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

Mon 12th October, 2020 12:45pm
For best results when printing this announcement, please click on link below:

CAMBRIDGE, Mass. and NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Black Diamond
Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company
pioneering the discovery and development of small molecule, tumor-agnostic
therapies, today announced that pre-clinical data on the Company’s lead
product candidate BDTX-189 will be presented at the 32(nd) EORTC-NCI-AACR
Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020)
taking place October 24-25, 2020.

Presentation details are as follows:

Title: BDTX-189, a potent and selective inhibitor of allosteric EGFR and HER2
oncogenic mutations
Presenter: Elizabeth Buck, Ph.D., Co-Founder and Executive Vice President,
Discovery and Translational Sciences, Black Diamond Therapeutics
Session: Closing Session: New Drugs on the Horizon
Date and Time: Sunday, October 25, 2020 at 21:00 CET/3:00 PM ET
Presentation Number: INV-006

Abstracts are available on the ENA 2020 conference website at

About BDTX-189

BDTX-189 is an orally available, irreversible small molecule inhibitor that is
designed to block the function of an undrugged family of oncogenic proteins
defined by driver mutations across a range of tumor types, and which affect
both of the epidermal growth factor receptor (EGFR) and the tyrosine-protein
kinase, ErbB-2, or human epidermal growth factor receptor 2 (HER2). These
mutations include extracellular domain allosteric mutations of HER2, as well
as EGFR and HER2 kinase domain exon 20 insertions, and additional activating
oncogenic drivers of ErbB. The ErbB receptors are a group of receptor tyrosine
kinases involved in key cellular functions, including cell growth and
survival. BDTX-189 is also designed to spare normal, or wild type EGFR, which
we believe has the potential to improve upon the toxicity profiles of current
ErbB kinase inhibitors.

Currently, there are no medicines approved by the U.S. Food and Drug
Administration to target all of these oncogenic mutations with a single

About Black Diamond

Black Diamond Therapeutics is a precision oncology medicine company pioneering
the discovery of small molecule, tumor-agnostic therapies. Black Diamond
targets undrugged mutations in patients with genetically defined cancers.
Black Diamond is built upon a deep understanding of cancer genetics, protein
structure and function, and medicinal chemistry. The Company’s proprietary
technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is
designed to allow Black Diamond to analyze population-level genetic sequencing
data to identify oncogenic mutations that promote cancer across tumor types,
group these mutations into families, and develop a single small molecule
therapy in a tumor-agnostic manner that targets a specific family of
mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth
Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began
building the MAP platform and chemistry discovery engine. For more
information, please visit


For Investors:
Natalie Wildenradt

For Media:
Kathy Vincent
(310) 403-8951


GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.